全文获取类型
收费全文 | 715篇 |
免费 | 60篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 33篇 |
儿科学 | 10篇 |
妇产科学 | 1篇 |
基础医学 | 121篇 |
口腔科学 | 38篇 |
临床医学 | 84篇 |
内科学 | 139篇 |
皮肤病学 | 12篇 |
神经病学 | 65篇 |
特种医学 | 11篇 |
外科学 | 96篇 |
综合类 | 16篇 |
预防医学 | 55篇 |
眼科学 | 23篇 |
药学 | 37篇 |
中国医学 | 2篇 |
肿瘤学 | 33篇 |
出版年
2023年 | 3篇 |
2022年 | 4篇 |
2021年 | 5篇 |
2020年 | 6篇 |
2019年 | 13篇 |
2018年 | 13篇 |
2017年 | 6篇 |
2016年 | 4篇 |
2015年 | 12篇 |
2014年 | 16篇 |
2013年 | 27篇 |
2012年 | 56篇 |
2011年 | 69篇 |
2010年 | 39篇 |
2009年 | 28篇 |
2008年 | 56篇 |
2007年 | 69篇 |
2006年 | 49篇 |
2005年 | 55篇 |
2004年 | 49篇 |
2003年 | 36篇 |
2002年 | 35篇 |
2001年 | 7篇 |
2000年 | 2篇 |
1999年 | 6篇 |
1998年 | 13篇 |
1997年 | 11篇 |
1996年 | 7篇 |
1995年 | 3篇 |
1994年 | 3篇 |
1993年 | 5篇 |
1992年 | 5篇 |
1991年 | 6篇 |
1990年 | 4篇 |
1989年 | 2篇 |
1986年 | 5篇 |
1985年 | 2篇 |
1984年 | 4篇 |
1983年 | 2篇 |
1982年 | 5篇 |
1980年 | 5篇 |
1978年 | 2篇 |
1977年 | 3篇 |
1976年 | 2篇 |
1975年 | 3篇 |
1974年 | 2篇 |
1972年 | 3篇 |
1962年 | 2篇 |
1961年 | 2篇 |
1914年 | 2篇 |
排序方式: 共有776条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Lorne M. Hartman Dr. 《Clinical psychology review》1983,3(4):435-456
This article represents an attempt to clarify questions posed by evidence of varying pathways to change in social anxiety. A new perspective is developed which addresses these questions and, importantly, lays the foundation for an innovative treatment approach. Essentially, social anxiety is construed here as the product of a disorganization in which feelings and cognitions (both conscious and preconscious) about the self, about other people, and about the relations between self and others are organized. Specifically, the socially anxious client experiences others autocentrically: that is, in terms of how the other person perceives, evaluates and affects one's own self. The result is a narrowed capacity for experiencing others. The goal of treatment in the new approach advocated here is to allow the individual to understand, appreciate and share the feelings, thoughts and experience of other people. Therapy is directed toward getting clients out of themselves and into other people. 相似文献
5.
6.
PURPOSE: The cost of darbepoetin alfa versus that of epoetin alfa in a hospital setting was studied. METHODS: The study was an observational, retrospective review of the hospitalwide use of darbepoetin and epoetin during hospital admissions beginning in the period from January 2003 through April 2003. After the identification from daily charge reports of patients who used at least one of the study drugs during an admission, charts were requested for review. Drug product costs were determined from hospital purchasing information. Material and labor costs were combined to estimate drug administration costs. Total costs were calculated as the sum of drug product costs and administration costs. RESULTS: A total of 429 epoetin records and 80 darbepoetin records were included. The two cohorts were similar with respect to demographic characteristics. With respect to costs, the only significant difference between cohorts was in daily administration costs, which were lower for patients receiving darbepoetin. Sensitivity analysis found lower costs for darbepoetin only after the dose-conversion ratio (DCR) was increased to above 256.74 units:1 microg. The overall DCR based on the median daily dose of each drug was 244.90 units:1 microg. CONCLUSION: A cost-minimization study in a hospital showed no cost difference between treatment with epoetin and darbepoetin. 相似文献
7.
Lorne A. Clarke Roberto Giugliani Nathalie Guffon Simon A. Jones Hillary A. Keenan Maria V. Munoz-Rojas Torayuki Okuyama David Viskochil Chester B. Whitley Frits A. Wijburg Joseph Muenzer 《Clinical genetics》2019,96(4):281-289
Mucopolysaccharidosis type I (MPS I) is a rare autosomal recessive disorder resulting from pathogenic variants in the α-L-iduronidase (IDUA) gene. Clinical phenotypes range from severe (Hurler syndrome) to attenuated (Hurler-Scheie and Scheie syndromes) and vary in age of onset, severity, and rate of progression. Defining the phenotype at diagnosis is essential for disease management. To date, no systematic analysis of genotype-phenotype correlation in large MPS I cohorts have been performed. Understanding genotype-phenotype is critical now that newborn screening for MPS I is being implemented. Data from 538 patients from the MPS I Registry (380 severe, 158 attenuated) who had 2 IDUA alleles identified were examined. In the 1076 alleles identified, 148 pathogenic variants were reported; of those, 75 were unique. Of the 538 genotypes, 147 (27%) were unique; 40% of patients with attenuated and 22% of patients with severe MPS I had unique genotypes. About 67.6% of severe patients had genotypes where both variants identified are predicted to severely disrupt protein/gene function and 96.1% of attenuated patients had at least one missense or intronic variant. This dataset illustrates a close genotype/phenotype correlation in MPS I but the presence of unique IDUA missense variants remains a challenge for disease prediction. 相似文献
8.
André Jastrzebski Alex Villafranca Subash Sethi Lorne Bellan 《Journal canadien d'anesthésie》2016,63(7):842-850
9.
10.